{"organizations": ["Cesca Therapeutics"], "uuid": "5ffa473d578db23569338ad7795e88f306b39269", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530670?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Regenerative medicine company Cesca Therapeutics secures $15mm in debt", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Regenerative medicine company Cesca Therapeutics secures $15mm in debt", "spam_score": 0.0, "site_type": "news", "published": "2015-09-09T02:40:00.000+03:00", "replies_count": 0, "uuid": "5ffa473d578db23569338ad7795e88f306b39269"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530670?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Regenerative medicine company Cesca Therapeutics secures $15mm in debt", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Regenerative medicine company Cesca Therapeutics secures $15mm in debt Deal Date: Sep-01-2015 / Deal # 201530670 Executive Summary \nRegenerative medicine company Cesca Therapeutics Inc raised an initial $5.5mm in senior secured debt and will receive another $9.5mm upon the achievement of certain milestones, including approval from the California Institute of Regenerative Medicine of the company's application for matching funds via a CIRM grant. The notes are interest free and can be converted into common shares at a strike price of $0.68. Cesca also issued Series A warrants to purchase up to 22.1mm common shares at $0.68 over 5.5 years, and Series B warrants for up to 12.1mm common shares at $0.68 over 18 months. The proceeds will be used for ongoing clinical initiatives.", "external_links": [], "published": "2015-09-09T02:40:00.000+03:00", "crawled": "2015-09-09T18:17:58.888+03:00", "highlightTitle": ""}